These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26883295)

  • 1. A collagen-binding EGFR antibody fragment targeting tumors with a collagen-rich extracellular matrix.
    Liang H; Li X; Wang B; Chen B; Zhao Y; Sun J; Zhuang Y; Shi J; Shen H; Zhang Z; Dai J
    Sci Rep; 2016 Feb; 6():18205. PubMed ID: 26883295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A collagen-binding EGFR single-chain Fv antibody fragment for the targeted cancer therapy.
    Liang H; Li X; Chen B; Wang B; Zhao Y; Zhuang Y; Shen H; Zhang Z; Dai J
    J Control Release; 2015 Jul; 209():101-9. PubMed ID: 25916496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacterial production and structure-functional validation of a recombinant antigen-binding fragment (Fab) of an anti-cancer therapeutic antibody targeting epidermal growth factor receptor.
    Kim JH; Sim DW; Park D; Jung TG; Lee S; Oh T; Ha JR; Seok SH; Seo MD; Kang HC; Kim YP; Won HS
    Appl Microbiol Biotechnol; 2016 Dec; 100(24):10521-10529. PubMed ID: 27470143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
    Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
    J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation of a human anti-epidermal growth factor receptor Fab antibody, EG-19-11, with subnanomolar affinity from naïve immunoglobulin repertoires using a hierarchical antibody library system.
    Hur BU; Yoon JB; Liu LK; Cha SH
    Immunol Lett; 2010 Nov; 134(1):55-61. PubMed ID: 20797408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile.
    Garrido G; Tikhomirov IA; Rabasa A; Yang E; Gracia E; Iznaga N; Fernández LE; Crombet T; Kerbel RS; Pérez R
    Cancer Biol Ther; 2011 Feb; 11(4):373-82. PubMed ID: 21150278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.
    Li S; Schmitz KR; Jeffrey PD; Wiltzius JJ; Kussie P; Ferguson KM
    Cancer Cell; 2005 Apr; 7(4):301-11. PubMed ID: 15837620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo imaging of protease activity by Probody therapeutic activation.
    Wong KR; Menendez E; Craik CS; Kavanaugh WM; Vasiljeva O
    Biochimie; 2016 Mar; 122():62-7. PubMed ID: 26546838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using ¹¹¹In-labeled bispecific radioimmunoconjugates.
    Razumienko E; Dryden L; Scollard D; Reilly RM
    Breast Cancer Res Treat; 2013 Apr; 138(3):709-18. PubMed ID: 23525982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.
    Mutsaers AJ; Francia G; Man S; Lee CR; Ebos JM; Wu Y; Witte L; Berry S; Moore M; Kerbel RS
    Clin Cancer Res; 2009 Apr; 15(7):2397-405. PubMed ID: 19276250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.
    Chen Y; Liu G; Guo L; Wang H; Fu Y; Luo Y
    Int J Cancer; 2015 Jan; 136(1):182-94. PubMed ID: 24798787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
    Fan Z; Masui H; Altas I; Mendelsohn J
    Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice.
    Hurwitz SJ; Zhang H; Yun S; Batuwangala TD; Steward M; Holmes SD; Rycroft D; Pan L; Tighiouart M; Shin HJ; Koenig L; Wang Y; Chen ZG; Shin DM
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):577-90. PubMed ID: 21913035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human IgG antibodies recognizing distinct extracellular domains of EGF receptor exhibit different degrees of growth inhibitory effects on human A431 cancer cells.
    Chang C; Takayanagi A; Yoshida T; Shimizu N
    Exp Cell Res; 2013 May; 319(8):1146-55. PubMed ID: 23499740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab.
    Patel D; Guo X; Ng S; Melchior M; Balderes P; Burtrum D; Persaud K; Luna X; Ludwig DL; Kang X
    Hum Antibodies; 2010; 19(4):89-99. PubMed ID: 21178280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
    Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure of the Fab fragment of the anti-murine EGFR antibody 7A7 and exploration of its receptor binding site.
    Talavera A; Mackenzie J; Garrido G; Friemann R; López-Requena A; Moreno E; Krengel U
    Mol Immunol; 2011 Jul; 48(12-13):1578-85. PubMed ID: 21592580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
    Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
    Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Wong TW; Kramer RA; Wild R; Lee FY
    Clin Cancer Res; 2005 Aug; 11(15):5558-65. PubMed ID: 16061873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.